Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate
-
By
-
March 18, 2026
Objective:
To evaluate serum TWEAK levels before and after therapy with adalimumab or methotrexate and correlate them with PASI and DAPSA indices to assess their potential as biomarkers for treatment response.
Key Findings:
- Serum TWEAK levels were significantly correlated with disease activity indices (PASI and DAPSA) (p < 0.05).
- Adalimumab and methotrexate showed differential effects on TWEAK modulation, with adalimumab leading to a greater reduction in TWEAK levels compared to methotrexate.
- Both treatments improved clinical outcomes in psoriasis and PsA patients, with PASI and DAPSA scores significantly decreased post-treatment.
Interpretation:
The study suggests that serum TWEAK levels may serve as a biomarker for monitoring treatment response in psoriasis and PsA.
Limitations:
- Lack of randomization may introduce bias, potentially affecting the generalizability of the results.
- Short follow-up period may not capture long-term treatment effects, necessitating further studies with extended follow-up.
Conclusion:
Serum TWEAK levels could be a valuable marker for assessing treatment outcomes in psoriasis and PsA, warranting further investigation to confirm these findings in larger, randomized studies.
